Factsheet and Information Brochure
Factsheet
Target Market
Costs and charges
Fund rules (136 kB)
Prospectus (1596 kB)
Periodic reports
Sustainability SFDR (1071 kB)
Annual review (PF) (3188 kB)
Semi-annual report (PF) (189 kB)
Marketing material
Brief fund information
Summary SFDR (168 kB)
AstraZeneca Allemansfond
Legal name: AstraZeneca Allemansfond
Equity Fund Registered in Sweden (Non-UCITS)
Bid
About risk
Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.
The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Fund manager
Ulrika Orstadius Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.
|
|
||
|---|---|---|---|
|
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
|
|
30.06.2025
|
||
|---|---|---|---|
|
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating |
|
|
||
|---|---|---|---|
|
This fund promotes environmental and social characteristics through its investments but does not have sustainable investments as its objective. As a result, the fund takes into consideration the environment and climate, as well as human rights, employees’ rights and corruption. The fund is reported as an Article 8 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR). |
|
30.04.2025
|
|||
|---|---|---|---|
|
The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating. The fund complies with the UN Principles for Responsible Investments. |
Graph
Performance
| Rate 10.07.2025 | 1 week | 1 month | 3 months | 2025 | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|
| 3,914.49 SEK | 1.39% | 0.62% | 10.50% | 1.40% | -3.54% | 82.30% | 223.09% |
Portfolio 09.07.2025
Portfolio manager comments — Q2 2025
Fund performance was negative during the second quarter.
The holdings with the most negative impact on fund returns were AstraZeneca, Hexagon and Essity. AstraZeneca underperformed due to concerns about tariffs and regulatory changes related to the healthcare sector in the US. Hexagon was negatively affected by its international exposure and sensitivity to the USD. Essity released a quarterly report that came in slightly below market expectations.
The strongest positive contributors were Autoliv, Sandvik and Beijer Ref, all of which delivered strong quarterly reports during the period.
Autoliv exceeded market expectations with results that demonstrated solid resilience. Sandvik also reported stable figures, which were well received in an otherwise uncertain market climate. Beijer Ref delivered a report above expectations and emphasized that the company had not seen any major negative impact from tariff concerns.
During the period, the fund added a new holding in Systemair, a global supplier of ventilation equipment that stands to benefit from a potential improvement in sentiment around the European construction market and energy efficiency in buildings. The fund also increased its holding in AstraZeneca to maintain a significant allocation after the share price declined, and reduced its holding in Assa Abloy due to its relatively high exposure to the US housing market.
We continue to focus on investee companies with sustainable business models and competitive offerings that support resilient and profitable growth.
Portfolio distribution 30.06.2025
Geographic breakdown 30.06.2025
